{"id":70596,"date":"2026-07-24T21:02:05","date_gmt":"2026-07-24T13:02:05","guid":{"rendered":"https:\/\/flcube.com\/?p=70596"},"modified":"2026-07-24T21:02:06","modified_gmt":"2026-07-24T13:02:06","slug":"aidea-pharma-secures-nmpa-approval-for-darunavir-challenging-jjs-prezista-in-chinas-hiv-treatment-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70596","title":{"rendered":"Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market"},"content":{"rendered":"\n

Jiangsu Aidea Pharmaceutical Group Co., Ltd.<\/strong> (SHA: 688488<\/a>) announced today that China’s National Medical Products Administration (NMPA)<\/strong> has granted marketing approval for its darunavir<\/strong> product, positioning the company to compete directly with Johnson & Johnson’s established Prezista<\/strong> brand in China’s HIV treatment market. The protease inhibitor is indicated for HIV-1 infection<\/strong> in antiretroviral therapy (ART)-experienced patients aged 3 years and older (weighing at least 40 kg) with darunavir resistance-associated mutations or when genotypic testing is unavailable.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>National Medical Products Administration (NMPA), China<\/td><\/tr>
Approval Type<\/strong><\/td>Marketing authorization for darunavir<\/td><\/tr>
Indication<\/strong><\/td>HIV-1 infection in ART-experienced patients with resistance mutations or untestable genotypes<\/td><\/tr>
Patient Population<\/strong><\/td>Adults and pediatric patients \u22653 years old, \u226540 kg<\/td><\/tr>
Administration<\/strong><\/td>Co-administered with ritonavir plus other antiretroviral agents<\/td><\/tr>
Approval Date<\/strong><\/td>24 Jul 2026<\/td><\/tr>
Originator<\/strong><\/td>Johnson & Johnson (original FDA approval: June 2006)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Landscape<\/h2>\n\n\n\n